| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
CBBR targets alpha-synuclein aggregation. It inhibits the aggregation of both wild type and mutant alpha-synuclein, which is a key pathological feature of Parkinson's disease and other synucleinopathies. As a modulator of neurotoxicity, it may protect against the toxic effects of alpha-synuclein aggregates.
|
|---|---|
| ln Vitro |
CBBR is an inhibitor of wild type and mutant alpha-synuclein aggregation. It also acts as a modulator of neurotoxicity. Its primary use, however, is as a protein stain in SDS-PAGE, where it binds to proteins and allows their detection.
|
| ln Vivo |
CBBR is used extensively as an analytical dye in SDS-PAGE for protein detection. In research, it has been studied for its ability to inhibit alpha-synuclein aggregation, suggesting potential applications in neurodegenerative disease research.
|
| Enzyme Assay |
CBBR's activity as an alpha-synuclein aggregation inhibitor is assessed using in vitro aggregation assays. These assays typically involve incubating alpha-synuclein with the compound and measuring aggregate formation using techniques such as Thioflavin T fluorescence or electron microscopy. Its protein-binding properties are assessed in SDS-PAGE applications.
|
| Cell Assay |
Cellular assays for CBBR involve treating cells expressing alpha-synuclein with the compound and measuring its effects on aggregation and toxicity. The compound's ability to reduce aggregate formation and protect against alpha-synuclein-induced cell death is assessed.
|
| Animal Protocol |
In vivo animal model protocols for CBBR would involve its administration to animal models of synucleinopathies to evaluate its effects on alpha-synuclein aggregation and neurotoxicity. However, its primary use remains as a laboratory reagent rather than a therapeutic compound.
|
| ADME/Pharmacokinetics |
CBBR (Coomassie Brilliant Blue R-250) has a molecular weight of 825.98 and a molecular formula of C45H44N3NaO7S2. It appears as a gray to dark purple to black powder or crystal. It has a maximum absorbance of 586.0 to 590.0 nm in methanol.
|
| Toxicity/Toxicokinetics |
CBBR is generally considered safe for laboratory use. As a dye, it is not intended for human consumption or therapeutic use. Standard laboratory safety precautions should be followed when handling the compound.
|
| References | |
| Additional Infomation |
CBBR (CAS# 6104-59-2) is a laboratory reagent used primarily as a protein stain in SDS-PAGE. It is also known as Brilliant Blue R, Acid Blue 83, and Coomassie Brilliant Blue R. In research, it has been studied as an inhibitor of alpha-synuclein aggregation.
|
| Molecular Formula |
C45H44N3NAO7S2
|
|---|---|
| Molecular Weight |
825.97
|
| Exact Mass |
825.251
|
| CAS # |
6104-59-2
|
| PubChem CID |
61365
|
| Appearance |
Brown to black solid powder
|
| Melting Point |
174-180 °C
|
| Flash Point |
14 °C
|
| LogP |
10.499
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
58
|
| Complexity |
1500
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
NKLPQNGYXWVELD-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C45H45N3O7S2.Na/c1-4-47(31-33-9-7-11-43(29-33)56(49,50)51)40-23-15-36(16-24-40)45(35-13-19-38(20-14-35)46-39-21-27-42(28-22-39)55-6-3)37-17-25-41(26-18-37)48(5-2)32-34-10-8-12-44(30-34)57(52,53)54;/h7-30H,4-6,31-32H2,1-3H3,(H2,49,50,51,52,53,54);/q;+1/p-1
|
| Chemical Name |
sodium;3-[[4-[[4-(4-ethoxyanilino)phenyl]-[4-[ethyl-[(3-sulfonatophenyl)methyl]azaniumylidene]cyclohexa-2,5-dien-1-ylidene]methyl]-N-ethylanilino]methyl]benzenesulfonate
|
| Synonyms |
Coomassie Brilliant Blue R250; Coomassie Brilliant Blue R; CBBR
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~60.53 mM)
H2O : ~2 mg/mL (~2.42 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1 mg/mL (1.21 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1 mg/mL (1.21 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2107 mL | 6.0535 mL | 12.1070 mL | |
| 5 mM | 0.2421 mL | 1.2107 mL | 2.4214 mL | |
| 10 mM | 0.1211 mL | 0.6053 mL | 1.2107 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
